Literature DB >> 21559737

Focal fat masquerading as malignancy in the liver graft of a post-transplant patient.

Caitlyn M Patrick1, Paul H Hayashi, Tomasz Kozlowski, Kevin G Greene, Richard C Semelka, A Sidney Barritt.   

Abstract

BACKGROUND AND AIMS: Liver failure from non-alcoholic fatty liver disease (NAFLD) is an increasing indication for liver transplant and recurrence of fatty liver in transplanted grafts has been documented. Herein is described an atypical recurrence of steatosis as a de novo focal fatty lesion that mimicked a more ominous cancerous lesion. This presentation of recurrent NAFLD has not previously been described in the literature.
METHODS: Chart review.
RESULTS: Biopsy of an atypical lesion was found to be focal fat with surrounding steatohepatitis.
CONCLUSIONS: Non-alcoholic fatty liver disease may recur after liver transplant and manifest as a focal fatty lesion. It is important to catalogue the atypical presentations of the increasingly common NAFLD developing in transplanted livers.

Entities:  

Mesh:

Year:  2011        PMID: 21559737      PMCID: PMC3308147          DOI: 10.1007/s10620-011-1739-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  13 in total

1.  Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation.

Authors:  R M Molloy; R Komorowski; R R Varma
Journal:  Liver Transpl Surg       Date:  1997-03

2.  Focal fat mimicking multiple hepatic metastases on FDG PET/CT imaging.

Authors:  Maurice H Zissen; Andrew Quon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-27       Impact factor: 9.236

3.  Prevalence and clinical associations of posttransplant fatty liver disease.

Authors:  Lee Guan Lim; Chee Leong Cheng; Aileen Wee; Seng Gee Lim; Yin Mei Lee; Dede Selamat Sutedja; Maureen Da Costa; K Prabhakaran; Chun-Tao Wai
Journal:  Liver Int       Date:  2007-02       Impact factor: 5.828

4.  The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes.

Authors:  A Sidney Barritt; Evan S Dellon; Tomasz Kozlowski; David A Gerber; Paul H Hayashi
Journal:  J Clin Gastroenterol       Date:  2011-04       Impact factor: 3.062

Review 5.  The metabolic effects of cyclosporin and tacrolimus.

Authors:  P Marchetti; R Navalesi
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

6.  Recurrence of nonalcoholic steatohepatitis following liver transplantation.

Authors:  W R Kim; J J Poterucha; M K Porayko; E R Dickson; J L Steers; R H Wiesner
Journal:  Transplantation       Date:  1996-12-27       Impact factor: 4.939

Review 7.  Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation.

Authors:  M S Cauble; R Gilroy; M F Sorrell; M E Mailliard; D L Sudan; J C Anderson; J L Wisecarver; S Balakrishnan; J L Larsen
Journal:  Transplantation       Date:  2001-04-15       Impact factor: 4.939

Review 8.  Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation.

Authors:  Anne Burke; Michael R Lucey
Journal:  Am J Transplant       Date:  2004-05       Impact factor: 8.086

9.  Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis.

Authors:  Shahid M Malik; Michael E Devera; Paulo Fontes; Obaid Shaikh; Eizaburo Sasatomi; Jawad Ahmad
Journal:  Liver Transpl       Date:  2009-12       Impact factor: 5.799

10.  Outcome after liver transplantation for NASH cirrhosis.

Authors:  S M Malik; M E deVera; P Fontes; O Shaikh; J Ahmad
Journal:  Am J Transplant       Date:  2009-04       Impact factor: 8.086

View more
  1 in total

1.  Assessment of the clinical efficacy of cell-assisted lipotransfer and conventional fat graft: a meta-analysis based on case-control studies.

Authors:  Yu Wang; Yanfei Wu
Journal:  J Orthop Surg Res       Date:  2017-10-19       Impact factor: 2.359

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.